Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. - Wikidata - awgldk - TriplyDB

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

http://www.wikidata.org/entity/Q35687716

about

Oral substitution treatment of injecting opioid users for prevention of HIV infection Update on the clinical use of buprenorphine: in opioid-related disorders Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience Update in addiction medicine for the generalist Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.Addiction treatment-related employment barriers: the impact of methadone maintenance Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.Buprenorphine Prescribing: To Expand or Not to Expand Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.Buprenorphine-naloxone therapy in pain management.Effect of buprenorphine dose on treatment outcome.Pharmacotherapies for treating opioid use disorder.Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective.Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices.A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program.Reimbursement and practice policies among providers of buprenorphine-naloxone treatment.Clinician recommendation of 12-step meeting attendance and discussion regarding disclosure of buprenorphine use among patients in office-based opioid treatment.Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes.A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.The Black Book of Psychotropic Dosing and Monitoring.Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.Suboxone: Rationale, Science, Misconceptions.Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

P2860

Q24234956-BA5BF354-AB7B-4EFF-9ABD-C3E106ACB886 Q26829140-5E9FBA90-9298-4053-8676-FC51F14E58B1 Q26865674-690D417B-9634-430E-93BE-253E72494920 Q33582068-2164FB4F-6443-43E0-A156-7B63F29FA2CD Q33719992-6214D1EF-EBEE-4312-BA04-5108BBBFDAC5 Q33760418-0C4BBFC9-4B8A-4D36-907E-D73BD556762F Q33845768-3B8532BC-A3D4-49FA-BA1A-D720038FCB8B Q34506003-B94E3357-1D2A-4AA3-BD1D-47806C0E69D5 Q35228546-2EC84EF0-73C0-49E4-BD44-713695DB6E11 Q35936860-01700BE9-6C53-4402-850B-5D0E21672585 Q35936977-0EA8A9DF-13D4-44E7-A251-A2A23654895B Q35980664-FE2226B7-E2AC-457C-8D94-0A0C5AC3C3E5 Q36030715-52C6F07D-22C2-4EF7-B7B2-C1430FE0348B Q36249927-6B8F3F6E-62F4-4EBF-9FE4-A95B3AC7AB79 Q36253355-8645AB4E-CB3A-484A-8FF9-0B523325D1E1 Q36476423-5524B7F5-D51F-421B-B3B9-44EF32C3B7E4 Q36711790-7F51663E-C89C-469B-AD50-2C6E25EB99EC Q36855631-41BD1540-93DD-4BF5-9F4E-571923F1C8C8 Q36906548-40F5BF3D-961F-4C02-B3AC-81613E0B46CE Q37722356-17133F52-99E6-48A4-BF07-AB8CDED8D410 Q37987271-FA1D9994-F783-4782-85C0-1561C4796364 Q38096571-87E4D4BA-5E07-48F1-91FE-BB5C8FD41ADE Q38244651-C0367537-3DD0-416B-8EC4-C4C796AEBD20 Q38562886-EA044556-314A-4B6D-9BD6-0672CD4CF81F Q38687655-4AE5789D-5D12-40CB-81E0-2975749577E0 Q38920347-A32982C8-01EF-4A4E-9529-1812406BE6C0 Q39009581-DDC18CE0-FEF5-446D-9CE0-9E6064113693 Q39039330-27EB7CC7-FC3D-4CC2-BE39-19D49B19CB9A Q40117638-DB49343C-4B71-4DF1-8484-1DBA3924F3F5 Q40216408-ACD70583-7685-4529-84A3-7000D692B34F Q41367554-73AB38FB-AFDA-43DD-ACD1-1409CF70386D Q42375619-81879607-691A-486C-B3F7-DEC7A9665BCC Q42594675-6D721591-B583-4AB2-B570-86EFC843B8A3 Q44334201-91939276-8008-444F-8A4F-FC6E1806D6C0 Q45847009-1F8548E6-DE30-40B8-939B-9F0F918C02AC Q47282815-10675145-F7CD-47F2-95E0-A5B4AF66BC50 Q47642128-284A19C7-D042-4ED7-A9B6-3AF445C4B72B Q47693045-B839EB4D-91C1-43E7-BA38-72018F99EAD2 Q52645984-D03426B8-3C2F-48E9-9519-39A7F876FD9C Q57492671-2D22A7FA-81BE-45B9-8DC8-F698914E7E0D

P2860

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

http://www.wikidata.org/entity/Q35687716

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@ast

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@en

type

label

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@ast

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@en

prefLabel

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@ast

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

@en

P1433

Q35687716-70C637C9-6BAE-4DD3-B689-B8769F9720E9

P1476

Q35687716-1F43E085-221E-4E9E-95DC-7324D12D7BF4

P2093

Q35687716-01790BE8-20D4-42BD-BEBB-9F12D0DE1196

Q35687716-4126E287-9452-470C-8150-2AF415A534AB

Q35687716-5A33D8E8-1797-4E35-82E9-0EF1DA425E53

Q35687716-933D264E-0D26-418C-9116-8328B0E6698C

Q35687716-96ACB3CE-4D20-427A-A2CE-0C8A83A84DB1

Q35687716-98126BFA-4AE8-4DEF-A5BF-8594A0D3763A

P2860

Q35687716-0257A527-B8D7-4765-9289-29CD71584424

Q35687716-0520FFD5-1EFA-4DAF-984B-446203BD45F7

Q35687716-08FEEE7D-A08B-4040-84D1-32BF064792B6

Q35687716-10B8DF1E-E18D-44DF-98BF-A699C533BC21

Q35687716-21426299-3DFA-4B6D-9A46-D4E89E6367BA

Q35687716-2601F662-168E-41EF-8348-B488D65FBC06

Q35687716-30F76759-165D-4CAA-B047-B328E260464A

Q35687716-310C94C1-80F2-4026-81D9-038DA740D3BE

Q35687716-31FA67E8-8D03-4C0C-B2B9-D538AF0741E9

Q35687716-428B7389-1D1D-42AF-BC3C-CAE9761C47E7

P304

Q35687716-01436266-7502-4854-BE8D-2B115C60F9E8

P31

Q35687716-4EA1BAE8-99D7-4AF8-A4F0-B0E6C3BFB8D8

P356

Q35687716-F5C0C9C4-2E8E-4551-BB8E-C5559BFEEB21

P433

Q35687716-3069370D-D8AC-4062-8159-8681F0C899F3

P478

Q35687716-58E7D3D8-0C23-4316-A78A-BADF07835568

P50

Q35687716-676B62EF-BB0E-4425-A95E-C28B76D8B519

P577

Q35687716-BDB8C411-2283-431C-BCDB-5E2748C7A202

P5875

Q35687716-B7A0A5A3-1AA0-4FC7-B5E6-1619E7EC11F6

P698

Q35687716-5ABF1198-6D66-498D-83AA-86E885A5A346

P932

Q35687716-611B2483-0862-4086-8ED5-965803A6568D

P356

J.DRUGALCDEP.2009.07.013

P1433

Drug and Alcohol Dependence

P1476

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy

@en

P2093

A G Mace

http://www.w3.org/2001/XMLSchema#string

B Merkin

http://www.w3.org/2001/XMLSchema#string

C A Adelman

http://www.w3.org/2001/XMLSchema#string

R A Ionescu

http://www.w3.org/2001/XMLSchema#string

R Defranco

http://www.w3.org/2001/XMLSchema#string

T V Parran

http://www.w3.org/2001/XMLSchema#string

P2860

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.

The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.

Buprenorphine retention in primary care.

Clinical practice. Office-based treatment of opioid-dependent patients.

From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Buprenorphine: how to use it right.

P304

56-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUGALCDEP.2009.07.013

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26777029

http://www.w3.org/2001/XMLSchema#string

P698

19717249

http://www.w3.org/2001/XMLSchema#string

P932

3263699

http://www.w3.org/2001/XMLSchema#string